Sanofi reviews

Upper management team is the worst I have seem. How is it possible that sanofi have all the worst management folks all in one place?

If new, innovative products are the lifeblood of the pharma industry, then Sanofi is in a truly anemic state. Major, late pipeline embarrassments abound. Most recently, the FDA denial of Lemtrada (the cornerstone of the Genzyme acquisiton), delays with lixisenatide, and of course the monumental development failure of rimonabant. Add to this scenario the swing and miss on devices such as iBGStar and Auvi-Q; a clear picture of a leadership miscarriage emerges. A culture of "Change Agents" has been deployed to distract attention from the ongoing hemorrhaging, anemia, and soon to be patent cliffs on cash cow donor Lantus. The "MS Franchise" is down to Augagio. Another round of early 2014 staff reductions will staunch the rate of bleeding, before more aggressive amputations are ordered. Sanofi will likely emerge a diminished shadow of its former self. Best advice for job seekers: Keep ones eyes wide open, hearing tuned in to outside channels, and resume at the ready.